BridgeBio Pharma (BBIO) Consolidated Net Income (2019 - 2025)
Historic Consolidated Net Income for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to -$184.9 million.
- BridgeBio Pharma's Consolidated Net Income fell 1259.21% to -$184.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$777.2 million, marking a year-over-year decrease of 7234.73%. This contributed to the annual value of -$543.3 million for FY2024, which is 1682.42% up from last year.
- As of Q3 2025, BridgeBio Pharma's Consolidated Net Income stood at -$184.9 million, which was down 1259.21% from -$183.8 million recorded in Q2 2025.
- In the past 5 years, BridgeBio Pharma's Consolidated Net Income ranged from a high of -$19.1 million in Q1 2024 and a low of -$267.4 million during Q4 2024
- In the last 5 years, BridgeBio Pharma's Consolidated Net Income had a median value of -$162.2 million in 2023 and averaged -$153.4 million.
- Per our database at Business Quant, BridgeBio Pharma's Consolidated Net Income soared by 8659.48% in 2024 and then crashed by 64071.27% in 2025.
- Over the past 5 years, BridgeBio Pharma's Consolidated Net Income (Quarter) stood at -$180.6 million in 2021, then increased by 19.62% to -$145.1 million in 2022, then crashed by 32.37% to -$192.1 million in 2023, then plummeted by 39.19% to -$267.4 million in 2024, then soared by 30.84% to -$184.9 million in 2025.
- Its last three reported values are -$184.9 million in Q3 2025, -$183.8 million for Q2 2025, and -$141.1 million during Q1 2025.